| |
| Device | TAXUS LIBERTE ATOM PACLITAXEL-ELUTING CORONARY STENT SYSTEM |
| Generic Name | Coronary drug-eluting stent |
| Applicant | Boston Scientific Corp One Scimed Pl. Maple Grove, MN 55311 |
| PMA Number | P060008 |
| Supplement Number | S008 |
| Date Received | 11/28/2008 |
| Decision Date | 05/21/2009 |
| Withdrawal Date | 12/06/2018 |
| Product Code |
NIQ |
| Docket Number | 09M-0255 |
| Notice Date | 06/03/2009 |
| Advisory Committee |
Cardiovascular |
| Clinical Trials | NCT00371748
|
| Supplement Type | Panel Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | Yes |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement APPROVAL TO EXPAND THE PRODUCT MATRIX TO INCLUDE THE 2.25 MM TAXUSLIBERTE PACLITAXEL-ELUTING CORONARY STENT SYSTEM. THIS DEVICE SIZE WILL BE MARKETED UNDER THETRADE NAME TAXUS LIBERTE ATOM PACLITAXEL-ELUTING CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE DELIVERY SYSTEMS), AND IS INDICATED FOR IMPROVING LUMINAL DIAMETER FOR THETREATMENT OF DE NOVO LESIONS IN NATIVE CORONARY ARTERIES > =2.25 MM TO <= 4.00 MM IN DIAMETER INLESIONS <= 28 MM IN LENGTH. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Post-Approval Study | Show Report Schedule and Study Progress |